...
首页> 外文期刊>Scientific reports. >On-chip combined radiotherapy and chemotherapy testing on soft-tissue sarcoma spheroids to study cell death using flow cytometry and clonogenic assay
【24h】

On-chip combined radiotherapy and chemotherapy testing on soft-tissue sarcoma spheroids to study cell death using flow cytometry and clonogenic assay

机译:软组织Sarcoma球状体上的片上组合放射治疗和化疗检测,使用流式细胞术和克隆原测定研究细胞死亡

获取原文
           

摘要

Radiotherapy (RT) and chemotherapy (CT) are the major therapeutics to treat cancer patients. Conventional in vitro 2D models are insufficient to study the combined effects of RT and CT towards optimized dose selection or drug screening. Soft-tissue sarcomas (STS) are rare cancers with profound social impacts as they affect patients of all ages. We developed a microfluidic device to form and culture STS spheroids to study the combined cytotoxicities of RT and CT. Uniformly-sized spheroids of two different cell lines, STS 93 and STS 117, were formed in the device. RT doses of 0.5?Gy, 2?Gy, and 8?Gy were used in combination with CT, doxorubicin at 2?μM and 20?μM. The spheroids culture chambers within the device were arranged in a 3?×?5 matrix form. The device was made “peelable”, which enabled us to collect spheroids from each treatment condition separately. Collected spheroids were dissociated into single cells and evaluated using flow cytometry and clonogenic assays. Through this workflow, we observed that STS 93 spheroids treated with doxorubicin die through apoptosis, whereas RT induced death through other pathways. Spheroids from the p53 mutant STS 117 cell line were more resistant to RT and doxorubicin. The developed device could be used for the discovery of new drugs and RT synergies.
机译:放射疗法(RT)和化疗(CT)是治疗癌症患者的主要治疗方法。常规的体外2D模型不足以研究RT和CT对优化剂量选择或药物筛选的组合效果。软组织肉瘤(STS)是罕见的癌症,具有深刻的社会影响,因为它们影响了所有年龄段的患者。我们开发了一种微流体装置,以形成和培养STS球状体,以研究RT和CT的合并细胞毒性。在装置中形成均匀尺寸的两个不同细胞系STS 93和STS 117的球状体。 Rt剂量为0.5?GY,2?GY和8?GY与CT,多柔比蛋白组合使用2Ωμm和20≤μm。装置内的球形培养室以3?×5矩阵形式布置。该装置被“可剥离”,使我们能够分别从每个治疗状况中收集球状体。将被收集的球体分离成单细胞,并使用流式细胞术和克隆原测定评估。通过这种工作流程,我们观察到通过凋亡,用多柔比星进行的STS 93球体用凋亡,而RT通过其他途径诱导死亡。来自P53突变体STS 117细胞系的球体更耐受RT和多柔比蛋白。开发的装置可用于发现新药和RT协同作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号